FWP
CORT icon

FAS Wealth Partners’s Corcept Therapeutics CORT Stock Holding History

FAS Wealth Partners’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.2M Buy
324,876
+2,506
+0.8% +$151K 1.47% 14
2026
Q1 		$13M Buy
322,370
+12,352
+4% +$462K 0.81% 31
2025
Q4 		$10.8M Buy
310,018
+1,700
+0.6% +$134K 0.7% 35
2025
Q3 		$25.6M Buy
308,318
+5,889
+2% +$426K 1.74% 12
2025
Q2 		$22.2M Buy
302,429
+2,166
+0.7% +$157K 1.64% 12
2025
Q1 		$34.3M Sell
300,263
-8,944
-3% -$544K 2.8% 8
2024
Q4 		$15.6M Sell
309,207
-6,542
-2% -$343K 1.31% 17
2024
Q3 		$14.6M Sell
315,749
-23
-0% -$817 1.16% 19
2024
Q2 		$10.3M Buy
315,772
+4,389
+1% +$120K 0.89% 27
2024
Q1 		$7.84M Buy
311,383
+1,092
+0.4% +$25.8K 0.7% 31
2023
Q4 		$10.1M Sell
310,291
-473
-0.2% -$13K 0.96% 25
2023
Q3 		$8.47M Sell
310,764
-7
-0% -$203 0.91% 23
2023
Q2 		$6.91M Buy
310,771
+5,745
+2% +$132K 0.87% 24
2023
Q1 		$6.61M Sell
305,026
-1,250
-0.4% -$27.4K 0.72% 31
2022
Q4 		$6.22M Buy
306,276
+6,700
+2% +$168K 0.7% 33
2022
Q3 		$7.68M Sell
299,576
-204
-0.1% -$5.46K 0.85% 25
2022
Q2 		$7.13M Buy
299,780
+10,155
+4% +$221K 0.75% 27
2022
Q1 		$6.52M Buy
289,625
+4,283
+2% +$91.1K 0.61% 30
2021
Q4 		$5.65M Sell
285,342
-300
-0.1% -$6.09K 0.52% 33
2021
Q3 		$5.62M Buy
285,642
+3,680
+1% +$77K 0.53% 31
2021
Q2 		$6.2M Buy
281,962
+45,921
+19% +$1.02M 0.58% 28
2021
Q1 		$5.62M Buy
236,041
+14,996
+7% +$400K 0.58% 32
2020
Q4 		$5.78M Buy
221,045
+5,415
+3% +$114K 0.66% 31
2020
Q3 		$3.75M Buy
215,630
+18,490
+9% +$295K 0.51% 37
2020
Q2 		$3.32M Sell
197,140
-5,357
-3% -$75.3K 0.49% 40
2020
Q1 		$2.41M Buy
+202,497
New +$2.51M 0.42% 45

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

FAS Wealth Partners's CORT Position: Q2 2026 in Review

FAS Wealth Partners increased its Corcept Therapeutics (CORT) stake by 0.78% in Q2 2026, buying an estimated $151K and bringing the position to 324,876 shares worth $28.2M. The position accounts for 1.47% of the portfolio, ranked #14.

FAS Wealth Partners first reported a position in CORT in Q1 2020 and has held it in 26 quarters since. The position peaked at $34.3M in Q1 2025. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • FAS Wealth Partners held 324,876 shares of Corcept Therapeutics worth $28.2M as of Q2 2026.
  • FAS Wealth Partners bought 2,506 Corcept Therapeutics shares in Q2 2026, an estimated $151K.
  • Corcept Therapeutics made up 1.47% of FAS Wealth Partners's portfolio in Q2 2026, its #14 holding.
  • FAS Wealth Partners first reported a position in Corcept Therapeutics in Q1 2020 and has held it in 26 quarters since.
  • FAS Wealth Partners's Corcept Therapeutics position peaked at $34.3M in Q1 2025.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on FAS Wealth Partners's 13F filing for Q2 2026, filed 29 Jul 2026.